A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

Launched by SHANDONG CANCER HOSPITAL AND INSTITUTE · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients who have been newly diagnosed with a type of cancer called Double Expression Diffuse Large B-cell Lymphoma (DLBCL). The treatment being tested combines a medication called orelabrutinib with a standard chemotherapy regimen known as R-CHOP. The goal is to see if this combination is safe and effective for patients before they have received any other treatments.

To participate in the trial, patients need to be between 18 and 70 years old and must have a confirmed diagnosis of DLBCL that hasn't been treated yet. They should also be in reasonably good health, with a life expectancy of at least three months. However, certain conditions like involvement of the brain by the lymphoma, severe heart or blood vessel issues, or active infections can exclude someone from joining. If eligible, participants will receive the new treatment and will be monitored closely for any side effects and how well the treatment is working. This study is currently recruiting participants, and it offers a chance to contribute to important research that could help improve treatment options for this type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma
• • Age 18-70 years
• • ECOG performance status 0-2
• • Ann Arbor stage II-IV
• • 8.Subjects who in line with the testing standard of the clinical trial laboratory
• • Life expectancy ≥ 3months
• Exclusion Criteria:
• • • systemic lymphoma involved CNS.
• • Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases.
• • uncontrolled infections (including HBV, HCV, HIV/AIDS)
• • Subjects who prepared for transplantation
• • Pregnancy or active lactation